Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Supinoxin provides encouraging tumor inhibition data
March 2016
EDIT CONNECT

SHARING OPTIONS:

ROCKVILLE, Md.—The American Society for Clinical Oncology (ASCO) 2016 Genitourinary Cancers Symposium saw Rexahn Pharmaceuticals Inc. present new preclinical efficacy data for Supinoxin (RX-5902), its novel anticancer drug candidate. The compound is an orally administered, potential first-in-class, small-molecule inhibitor of phosphorylated-p68 (P-p68), which increases the activity of multiple cancer-related genes and plays a role in tumor progression and metastasis. Over-expression of P-p68 has been seen in solid tumors in melanoma, colon, ovarian and lung cancers. One study suggested Supinoxin achieved tumor growth inhibition of more than 60 percent in a xenograft model of renal cell cancer. Another xenograft study suggested it achieved dose-dependent tumor growth inhibition of more than 60 percent and a partial clinical response in 60 percent of the animals and a complete response in 10 percent of the animals at a dose of 70 mg/kg.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.